A Study to Assess the Burden of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged Sixty Years and Above - Full Text View

Purpose

The study aims to estimate the incidence of herpes zoster (HZ), proportion of postherpetic neuralgia (PHN) and the economic burden and impact on quality of life, in Japanese adults greater than or equal to sixty years of age.

Condition	Intervention
Herpes Zoster	Other: Data collection


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Physician-practice Based Cohort Study to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Japan

Resource links provided by NLM:

MedlinePlus related topics: Shingles

U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

Total number of HZ cases reported in the study area, overall and within a specific age-group and gender. The following age-groups will be considered: 60-69, 70-79 and ≥ 80 years of age. [ Time Frame: Approximately 1 year ] [ Designated as safety issue: No ]
Occurrence of HZ-associated PHN pain, persisting between 90 and 270 days after the initial visit for this study. [ Time Frame: Day 90 - Day 270 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Occurrence of HZ-associated hospitalisations. [ Time Frame: Day 0 - Day 270 ] [ Designated as safety issue: No ]
Occurrence of HZ-associated any pain, persisting between 0 and 270 days after the initial visit for this study. [ Time Frame: Day 0 - Day 270 ] [ Designated as safety issue: No ]
Anamnestic information, clinical parameters and complications related to HZ. [ Time Frame: Day 0 - Day 270 ] [ Designated as safety issue: No ]
Direct medical, direct non-medical and indirect costs related to HZ. [ Time Frame: Day 0 - Day 90 ] [ Designated as safety issue: No ]
Quality of life (QoL) assessment in HZ subjects. [ Time Frame: Day 0 - Day 90 ] [ Designated as safety issue: No ]
Direct medical, direct non-medical and indirect costs related to PHN. [ Time Frame: Day 90 - Day 270 ] [ Designated as safety issue: No ]
QoL assessment in PHN subjects. [ Time Frame: Day 90 - Day 270 ] [ Designated as safety issue: No ]
Impact of the following factors on the development of PHN: - age, - gender, - concomitant disease, - current immunosuppressive therapy, - HZ severity at first consultation, - timing of initiation of treatment with antiviral agent etc. [ Time Frame: Day 0 - Day 270 ] [ Designated as safety issue: No ]


Enrollment:	448
Study Start Date:	June 2013
Study Completion Date:	February 2015
Primary Completion Date:	September 2014 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
Prospective Group Japanese adults, aged greater than or equal to sixty years, diagnosed with HZ.	Other: Data collection Case report forms (CRFs), logbooks and booklets.

Eligibility


Ages Eligible for Study:	60 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Japanese adults, male or female, greater than or equal to sixty years of age, presenting with HZ at the participating sites.

Criteria

Inclusion Criteria:

Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
Written informed consent obtained from the subject.
A male or female greater than or equal to sixty years of age, presenting with HZ at the time of enrollment.
HZ diagnosis.
- Is the subject's first outpatient diagnosis for this HZ episode. OR
- Took place up to seven days prior to the initial visit for the present study. Note: Recurrent HZ cases may be enrolled as new cases based on the investigator's clinical practice.

Exclusion Criteria:

• Not applicable.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01873365

Locations


Japan
GSK Investigational Site
Hokkaido, Japan, 084-0906
GSK Investigational Site
Hokkaido, Japan, 084-0909
GSK Investigational Site
Hokkaido, Japan, 084-0912
GSK Investigational Site
Hokkaido, Japan, 085-0014
GSK Investigational Site
Hokkaido, Japan, 085-0032
GSK Investigational Site
Hokkaido, Japan, 085-0036
GSK Investigational Site
Hokkaido, Japan, 085-0052
GSK Investigational Site
Hokkaido, Japan, 085-0057
GSK Investigational Site
Hokkaido, Japan, 085-0062
GSK Investigational Site
Hokkaido, Japan, 085-0063
GSK Investigational Site
Hokkaido, Japan, 085-0805
GSK Investigational Site
Hokkaido, Japan, 085-0813
GSK Investigational Site
Hokkaido, Japan, 085-0822
GSK Investigational Site
Hokkaido, Japan, 085-8533

Sponsors and Collaborators

GlaxoSmithKline

Investigators


Study Director:	GSK Clinical Trials	GlaxoSmithKline

More Information


Responsible Party:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT01873365 History of Changes
Other Study ID Numbers:	200089
Study First Received:	June 6, 2013
Last Updated:	April 16, 2015
Health Authority:	Japan: Ministry of Health, Labor and Welfare

Keywords provided by GlaxoSmithKline:


Quality of life Japan Adults Health economics	Herpes zoster Postherpetic neuralgia Physician-practice

Additional relevant MeSH terms:


Neuralgia Herpes Zoster Neuralgia, Postherpetic Pain Neurologic Manifestations Nervous System Diseases	Peripheral Nervous System Diseases Neuromuscular Diseases Signs and Symptoms Herpesviridae Infections DNA Virus Infections Virus Diseases

ClinicalTrials.gov processed this record on September 30, 2016